CN Patent
CN104039790B — 嘌呤衍生物及它们在治疗疾病中的应用
Assigned to Novartis AG · Expires 2016-04-13 · 10y expired
What this patent protects
本发明涉及式(I)的PI3K抑制剂,其中所有变量如说明书中所定义,涉及它们的制备、它们的医药应用、特别是它们在治疗癌症和神经变性疾病中的应用、及包含它们的药物。
USPTO Abstract
本发明涉及式(I)的PI3K抑制剂,其中所有变量如说明书中所定义,涉及它们的制备、它们的医药应用、特别是它们在治疗癌症和神经变性疾病中的应用、及包含它们的药物。
Drugs covered by this patent
- Balversa (ERDAFITINIB) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.